MedTrace Logo

Endothelin Receptor Antagonism in Proteinuric Nephropathy

NCT00722215 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 22

Last updated 2008-07-25

No results posted yet for this study

Summary

The number of people with kidney problems is increasing rapidly, related in part to the increasing prevalence of diabetes. Patients with kidney problems tend to have protein leaking into the urine (proteinuria). Both proteinuria and the kidney disease itself are associated with an increased risk of heart disease. Reducing proteinuria is an important treatment goal in people with kidney problems. Endothelin is a chemical produced both by blood vessels and the kidney. Higher than normal levels of endothelin are thought to contribute to progression of kidney disease and proteinuria. By using drugs that block the effects of endothelin ('endothelin receptor antagonists') we can hopefully reduce both of these. The purpose of the study is to ascertain whether endothelin receptor antagonists improve kidney function and reduce proteinuria more so than other commonly used drugs.

Conditions

Interventions

DRUG

BQ-123 (selective endothelin A receptor antagonist)

Single dose of BQ-123 given at a dose of 1000 nmol/min for 15 min intravenously.

DRUG

0.9 % saline

Single 15ml 0.9% saline infused for 15 mins as placebo control

DRUG

Nifedipine

Single dose of nifedipine 10 mg given orally as active control

Sponsors & Collaborators

  • British Heart Foundation

    collaborator OTHER

  • University of Edinburgh

    lead OTHER

Principal Investigators

  • Neeraj Dhaun, MBChB · University of Edinburgh

  • David J Webb, MD · University of Edinburgh

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
TRIPLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-05-31
Primary Completion
2007-11-30
Completion
2007-12-31

Countries

  • United Kingdom

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00722215 on ClinicalTrials.gov